May 21 |
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
|
May 17 |
Inventiva receives positive recommendation from DMC for late stage trial of NASH treatment
|
May 16 |
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
|
May 13 |
Why Is Inventiva's Stock Trading Higher on Monday?
|
May 13 |
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
|
Apr 3 |
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
|
Apr 1 |
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript
|
Mar 28 |
Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript
|
Mar 28 |
Inventiva announces the nomination of Andre Turenne as Director
|
Mar 27 |
Inventiva GAAP EPS of -€2.43, revenue of €17.48M
|